BUD23: A Promising Drug Target for Disabilities (G114049)

Target Name: BUD23

NCBI ID: G114049

BUD23

BUD23: A Promising Drug Target for Disabilities

BUD23, also known as Williams-Beuren syndrome chromosome region 22, is a gene that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

The BUD23 gene is located on chromosome 22, which is the second chromosome in the set. It contains several hundred genes that have not yet been fully characterized, but research has shown that it is involved in a number of important cellular processes, including cell division, growth, and differentiation.

One of the most promising aspects of the BUD23 gene is its potential as a drug target. The BUD23 gene has been shown to be involved in a number of diseases and disorders, including cancer, neurodegenerative diseases, and psychiatric disorders. Researchers are investigating the potential uses of drugs that target the BUD23 gene in order to treat these conditions.

For example, researchers have found that BUD23 is involved in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer. They have also shown that BUD23 is involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. In addition, BUD23 has been linked to a number of psychiatric disorders, including depression and anxiety.

Despite the potential benefits of targeting the BUD23 gene, there are also concerns about the potential drawbacks of doing so. For example, drugs that target the BUD23 gene have the potential to cause unintended side effects, such as nausea, vomiting, and muscle weakness. In addition, there is a risk that targeting the BUD23 gene may actually contribute to the development of new diseases, as has been seen in some cases with the use of gene-based therapies.

Overall, the BUD23 gene is an promising target for drug development due to its involvement in a number of diseases and disorders. While more research is needed to fully understand the potential uses of drugs that target the BUD23 gene, it is an important area of research that could lead to new and effective treatments for a variety of conditions.

Protein Name: BUD23 RRNA Methyltransferase And Ribosome Maturation Factor

Functions: S-adenosyl-L-methionine-dependent methyltransferase that specifically methylates the N(7) position of a guanine in 18S rRNA (PubMed:25851604). Requires the methyltransferase adapter protein TRM112 for full rRNA methyltransferase activity (PubMed:25851604). Involved in the pre-rRNA processing steps leading to small-subunit rRNA production independently of its RNA-modifying catalytic activity (PubMed:25851604). Important for biogenesis end export of the 40S ribosomal subunit independent on its methyltransferase activity (PubMed:24086612). Locus-specific steroid receptor coactivator. Potentiates transactivation by glucocorticoid (NR3C1), mineralocorticoid (NR3C2), androgen (AR) and progesterone (PGR) receptors (PubMed:24488492). Required for the maintenance of open chromatin at the TSC22D3/GILZ locus to facilitate NR3C1 loading on the response elements (PubMed:24488492). Required for maintenance of dimethylation on histone H3 'Lys-79' (H3K79me2), although direct histone methyltransferase activity is not observed in vitro (PubMed:24488492)

The "BUD23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BUD23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets